Literature DB >> 12915117

Osteopontin contributes to hepatocyte growth factor-induced tumor growth and metastasis formation.

E V Ariztia1, V Subbarao, D B Solt, A W Rademaker, A P Iyer, Z N Oltvai.   

Abstract

The cytokine hepatocyte growth factor (HGF)/scatter factor-1 and its cognate receptor, Met, are involved in the etiology and progression of many types of cancer. Despite recent advances in understanding the signal transduction pathways activated by HGF, the mechanism by which HGF exerts its tumorigenic effect is not well understood. To identify proteins that may be involved in mediating HGF-induced cell motility, invasiveness, and tumorigenesis, we used two separate differential display screening methods to identify changes in gene expression that are initiated by HGF in an epithelial cell culture system. Among several known and unknown genes whose expression was modified, osteopontin (OPN), a protein previously associated with tumorigenesis, was found to be upregulated within 6 h following HGF stimulation. OPN expression was dependent on activation of the PI-3 kinase pathway. Autocrine secretion of HGF resulted in sustained expression of OPN. Downregulation of opn expression by stable antisense transfection attenuated OPN expression and repressed HGF-induced invasiveness in vitro and decreased HGF-mediated tumor growth and metastasis formation in vivo. Constitutive expression of OPN in itself exerted partial invasiveness in vitro, but its expression itself was not sufficient to initiate tumor growth or metastasis formation in vivo. Thus, together with other molecules, OPN activity contributes to HGF-induced tumor growth and invasiveness.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12915117     DOI: 10.1016/s0014-4827(03)00118-6

Source DB:  PubMed          Journal:  Exp Cell Res        ISSN: 0014-4827            Impact factor:   3.905


  7 in total

1.  Expression of osteopontin and CD44 molecule in papillary renal cell tumors.

Authors:  Koviljka Matusan; Gordana Dordevic; Vladimir Mozetic; Ksenija Lucin
Journal:  Pathol Oncol Res       Date:  2005-07-01       Impact factor: 3.201

Review 2.  Osteopontin is a promoter for hepatocellular carcinoma metastasis: a summary of 10 years of studies.

Authors:  Lunxiu Qin
Journal:  Front Med       Date:  2014-01-25       Impact factor: 4.592

3.  Genomic aberrations in hepatocellular carcinoma related to osteopontin expression detected by array-CGH.

Authors:  Jin-Cai Wu; Bing-Sheng Sun; Ning Ren; Qing-Hai Ye; Lun-Xiu Qin
Journal:  J Cancer Res Clin Oncol       Date:  2009-10-16       Impact factor: 4.553

4.  Urinary aHGF, IGFBP3 and OPN as diagnostic and prognostic biomarkers for prostate cancer.

Authors:  Alisa J Prager; Cynthia R Peng; Elena Lita; Debbie McNally; Aradhana Kaushal; Mary Sproull; Kathryn Compton; William L Dahut; William D Figg; Deborah Citrin; Kevin A Camphausen
Journal:  Biomark Med       Date:  2013-12       Impact factor: 2.851

5.  c-Met activation through a novel pathway involving osteopontin mediates oncogenesis by the transcription factor LSF.

Authors:  Byoung Kwon Yoo; Rachel Gredler; Dong Chen; Prasanna K Santhekadur; Paul B Fisher; Devanand Sarkar
Journal:  J Hepatol       Date:  2011-04-13       Impact factor: 25.083

6.  Global analysis of DNA methylation in early-stage liver fibrosis.

Authors:  Yoko Komatsu; Tsuyoshi Waku; Naoya Iwasaki; Wakana Ono; Chie Yamaguchi; Junn Yanagisawa
Journal:  BMC Med Genomics       Date:  2012-01-27       Impact factor: 3.063

Review 7.  Role of osteopontin in tumour progression.

Authors:  S R Rittling; A F Chambers
Journal:  Br J Cancer       Date:  2004-05-17       Impact factor: 7.640

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.